GH stock sentiment todayGuardant Health, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
GH
Guardant Health, Inc.The FDA approval of Shield positions Guardant as a first-mover in the massive non-invasive colorectal cancer screening market, outweighing short-term cash burn.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GH. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the recent landmark FDA approval of Shield, the company's blood-based colorectal cancer (CRC) screening test. While the price quote provided ($178.8) likely reflects a pre-split or adjusted technical anomaly (actual trading is near $28-30), the market chatter centers on Medicare coverage expansion and the potential to disrupt the colonoscopy/Cologuard duopoly.
- ·FDA approval of Shield as a primary screening option
- ·Payer reimbursement negotiations and inclusion in clinical guidelines (USPSTF)
- ·Biopsy-free cancer monitoring growth in the clinical oncology segment
Financial
Revenue growth remains robust (20-25% YoY), driven by high volume in precision oncology. However, the company remains unprofitable with significant R&D spend. The balance sheet is cushioned by ~$1.1B in cash and equivalents, providing a runway for the Shield commercial launch.
- ·Revenue growth: 25% YoY (Q2 2024)
- ·Gross Margins: Strengthening at ~60%
- ·Cash Position: ~$1.1 billion vs. ~$350M annual burn
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow hype — the story is loud but nobody with skin in the game is buying.
- ·Insiders sold a net $2.6M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Strict FDA labeling regarding 'advanced adenoma' detection rates compared to colonoscopies
- ·High cash burn rate delaying the path to GAAP profitability
- ·Execution risk in a highly competitive diagnostic sales environment
Peer temperature
How direct competitors stack up against GH right now.
- NEUTRALEXASExact Sciences
COLDER — Facing a direct threat to Cologuard market share from GH's blood-based test, despite having superior cash flow.
See full analysis → - HOTNTRANatera, Inc.
HOTTER — Demonstrating faster paths to profitability and dominant market share in the MRD (Minimal Residual Disease) space.
See full analysis → - COLDILMNIllumina, Inc.
COLDER — Struggling with legacy GRAIL divestiture fallout and stagnant core sequencing hardware growth.
See full analysis →
- GH+0.2%
- EXAS—
- NTRA+0.2%
- ILMN-13.8%
Analyst price target
Consensus average of 22 analysts · median 200.00
Source: StockAnalysis.com · updated 2026-10-27
AI-generated analysis for informational purposes only. Not financial advice.